摘要
氯吡格雷用于预防冠心病患者经皮冠状动脉介入术(PCI)后的血栓事件,但仍有4%~30%的患者在常规剂量治疗中达不到预期效果。研究者把常规治疗剂量氯吡格雷在血小板功能试验中未能达到预期的抗血小板作用,仍有临床事件的发生,称为氯吡格雷低反应或无反应,即氯吡格雷抵抗。
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2013年第7期626-628,共3页
Chinese Journal of Cardiology
参考文献39
-
1Gremmel T, Panzer S. Clinical, genetic and confounding factorsdetermine the dynamics of the in vitro response/non response toclopidogrel. Thromb and haemost,2011,106:211-218.
-
2Park KW, Park JJ, Jeon KH, et al. Clinical predictors of highposttreatment platelet reactivity to clopidogrel in Koreans.Cardiovasc Ther, 2012, 30:5-11.
-
3Gurbel PA,Bliden KP,Hiatt BL,et al. Clopidogrel for coronarystenting: response variability, drug resistance, and the effect ofpretreatment platelet reactivity. Circulation, 2003,107 : 2908-2913.
-
4Cuisset T, Frere C, Quilici J, et al. Role of the T744Cpolymorphism of the P2Y12 gene on platelet response to a 600-mgloading dose of clopidogrel in 597 patients with non-ST-segmentelevation acute coronary syndrome. Thromb Res, 2007,120 :893-899.
-
5Malek LA,Spiewak M,Filipiak KJ,et al. Persistent plateletactivation is related to very early cardiovascular events in patientswith acute coronary syndromes. Kardiol Pol, 2007 , 65:40*45.
-
6Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrelloading doses according to vasodilator-stimulated phosphoproteinphosphorylation index decrease rate of major adverse cardiovascularevents in patients with clopidogrel resistance : a multicenterrandomized prospective study. J Am Coll Cardiol, 2008, 51:1404-1411.
-
7Farhan S, Hochtl T, Kautzky-Willer A, et al. Antithrombotictherapy in patients with coronary artery disease and with type 2diabetes mellitus. Wien Med Wochenschr, 2010,160:30-38.
-
8Harding SA, Sarma J, Din JN, el al. Clopidogrel reduces platelet-leucofyte aggregation,monocyte activation and RANTES secretionin type 2 diabetes mellitus. Heart, 2006, 92 ; 1335-1337.
-
9Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochromeP450 2C19 loss-of-function polymorphism and of majordemographic* characteristics on residual platelet function afterloading and maintenance treatment with clopidogrel in patientsundergoing elective coronary stent placement. J Am Coll Cardiol,2010, 55:2427-2434.
-
10Erlinge D, Varenhorst C, Braun OO, et al. Patients with poorresponsiveness to thienopyridine treatment or with diabetes havelower levels of circulating active metabolite, but their plateletsrespond normally to active metabolite added ex vivo. J Am CollCardiol,2008, 52 : 1968-1977.
二级参考文献12
-
1de la Torre-Hernandez JM, Alfonso F, Hernaindez F, et al. Drug- eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA. J Am Coil Cardiol, 2008, 51 : 986-990.
-
2Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol, 2005,45:1157-1164.
-
3Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stentiug are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12- month follow-up. Circulation, 2009, 119:237-242.
-
4Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J, 2008, 29:992-1000.
-
5von Beckerath N, Pogatsa-Murray G, Wieczorek A, et al. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost, 2006, 95:910 -911.
-
6Suh JW, Lee SP, Park KW, et al. Muhicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of eilostazol- based triple antiplatelet therapy on ischemic complication 'after drug-eluting stent implantation) trial. J Am Coil Cardiol, 2011, 57:280-289.
-
7Price M J, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRA VITAS randomized trial. .lAMA, 2011, 305 : 1097-1105.
-
8Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of elopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol, 2009, 54 : 1935-1945.
-
9Dorsch MP, Lee JS, Lynch DR, et al. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother, 2007, 41: 737-741.
-
10Ueno M, Ferreiro JL, Tomasello SD, et al. Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. Thromb Haemost, 2011, 105:730-732.
共引文献13
-
1潘建生,方汉云,李碎朋,陈勇.2型糖尿病合并冠心病患者氯吡格雷抵抗的危险因素[J].中华全科医学,2014,12(3):403-404. 被引量:4
-
2胡小飞.老年2型糖尿病合并冠心病患者氯吡格雷抵抗的发生及危险因素探讨[J].当代医学,2014,20(8):134-135. 被引量:7
-
3吕海辰,吴鸿谊,葛均波.急性冠脉综合征患者氯吡格雷抵抗的研究进展[J].大连医科大学学报,2014,36(4):387-392. 被引量:2
-
4阮爱兵.氯吡格雷抵抗机制的研究进展[J].河北联合大学学报(医学版),2015,17(4):79-82. 被引量:6
-
5张磊,梁迎春,宁方波,李洪军,王涛.氯吡格雷反应性与神经介入手术血管事件相关性研究[J].神经损伤与功能重建,2015,10(4):304-306.
-
6郑腾飞.氯沙坦、厄贝沙坦对老年高血压患者血小板活性的影响对比分析[J].社区医学杂志,2016,14(2):40-42.
-
7韩升波,郭三强,李琳.氯吡格雷抵抗患者的预测评分方法的探索[J].中国卫生检验杂志,2016,26(1):87-89.
-
8张萍,张虹,王贤良,王帅,毛静远.老年急性冠脉综合征患者PCI术后氯吡格雷抵抗危险因素分析[J].山东医药,2016,56(34):55-57. 被引量:12
-
9刘洪恩,何锡宁,陈建梅,丁宝忠,陈汝伟,翟秀云,周运波.血管支架置入辅助弹簧圈栓塞术后的颅内动脉瘤患者氯吡格雷抵抗影响因素分析[J].山东医药,2017,57(11):49-51. 被引量:16
-
10蔡飞,崔翰斌.吸烟对男性急性冠脉综合征患者氯吡格雷抗血小板作用的影响[J].现代实用医学,2017,29(7):877-879. 被引量:2
同被引文献56
-
1韩雅玲,梁明,荆全民,王守力,马颖艳,栾波.52例冠状动脉支架内血栓形成患者的临床特点及介入治疗[J].中华心血管病杂志,2006,34(11):975-978. 被引量:34
-
2Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxebeluting stents [J]. Circulation, 2006,113 (8) :1108-1113.
-
3Kirtane AJ, Stone GW. How to minimize stent thrombosis [J]. Circulation, 2011, 124(11) 1283-1287.
-
4Machecourt J Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetie patients the EVASTENT Matched- Cohort Registry[J]. J Am Coil Cardiol,2007,50(6) :501 508.
-
5Nusca A,Patti G. Platelet function and inhibition in ischemic heart disease [J]. Curt Cardiol Rep,2012,14(4) : 457-467.
-
6Lau WC,Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopideogrel to inhabit platelet aggregation: a new drug-drug interaction [J]. Circulation, 2003, 107 ( 1 ) : 32- 37.
-
7Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and elopidogrel: result from the interaction study[J]. Arch Intern Med,2004,164(18) 2051-2057.
-
8Sommer P, Armstrong EJ. Stent thrombosis current management and outcomes[J]. Curr Treat Options Cardiovasc Med, 2015,17 (3) : 365.
-
9Tsoukas A,Andonakoudis H,Christakos S.Short-term exercise training effect after myocardial infarction on myocardial oxygen consumption indices[J].Arch Phys Med Rehabil,1995,76:262-265.
-
10李森林,杜佩珊.氯吡格雷联合阿昔莫司对冠心病患者颈动脉的影响[C].//第七届华北长城心脏病学会议、河北省心血管病学2014年会暨第三届经前臂(桡/尺)动脉微创化冠脉介入治疗国际论坛论文集.2014:273-273.
引证文献7
-
1胡福莉,王天红,刘美霞,袁华兵,倪艳辉,曹广运,张清芬,袁静,许玉芳,王文静.抗血小板药物抵抗致冠状动脉支架植入术后亚急性血栓2例并文献复习[J].临床荟萃,2015,30(12):1352-1355. 被引量:1
-
2陈云江,龚艳春.氯吡格雷治疗冠心病患者的临床疗效观察[J].心脑血管病防治,2016,16(2):122-123. 被引量:8
-
3刘静,张铁亮,戴远辉,黄定.幽门螺杆菌感染与经皮冠状动脉介入治疗术后抗血小板治疗诱发上消化道出血的关系[J].中国循环杂志,2016,31(11):1060-1063. 被引量:15
-
4吴瑛,张晓星,田蕾,蒋娟娟,许莉,黄一玲,刘红,李一石.冠心病经皮冠状动脉介入治疗后服用氯吡格雷患者CYP2C19基因型和血小板聚集率变化与临床预后的相关性[J].中华心血管病杂志,2017,45(5):377-385. 被引量:24
-
5高晗清,薛群,段晓宇,朱珏华,方琪.CYP2C19基因多态性与症状性颅内动脉狭窄患者氯吡格雷反应性及早期神经功能恶化的相关性[J].中山大学学报(医学科学版),2017,38(6):854-859. 被引量:1
-
6王萌萌,柯福升.冠心病合并糖尿病患者行经皮冠状动脉介入治疗后CD62p与氯吡格雷抵抗的相关性研究[J].药物评价研究,2017,40(11):1593-1596. 被引量:3
-
7李燕.长期应用氯吡格雷及阿司匹林患者根除幽门螺杆菌对发生上消化道再出血的意义[J].甘肃科技,2018,34(1):115-116. 被引量:2
二级引证文献54
-
1解淑蕊,黄茜,岳亚光,李雅然,赵慧敏,韩宝娟,李帅,薛敏捷.Hp感染与服用抗血小板药物对老年患者上消化道出血影响的研究[J].中国中西医结合消化杂志,2020,28(2):112-115. 被引量:4
-
2程赟赟.1例急性下壁心肌梗死合并消化道出血患者的护理[J].世界最新医学信息文摘,2019,0(101):295-295. 被引量:1
-
3独孤昌军.钙离子拮抗剂对冠心病行经冠状动脉介入术后联合氯吡格雷治疗预后的影响[J].世界最新医学信息文摘,2020(55):94-95.
-
4陈越,张冬颖.抗HP治疗与PCI术后DAPT患者上消化道出血关系的研究进展[J].世界最新医学信息文摘,2020(18):15-17.
-
5刘希刚.试析氯吡格雷预防冠心病介入治疗心血管的临床疗效[J].智慧健康,2018,4(30):131-132. 被引量:2
-
6李伟玲.阿司匹林联合替罗非班预防冠心病PCI术后血栓形成100例分析[J].陕西医学杂志,2017,46(1):112-114. 被引量:39
-
7顾婕,田金萍,史冬梅,何丽.1例急性心肌梗死择期PCI术后合并上消化道出血及室颤患者的护理[J].实用临床医药杂志,2017,21(10):203-205. 被引量:6
-
8何晓雷,杨丽,孙稳.替格瑞洛与氯吡格雷治疗冠心病心肌缺血的临床疗效对比[J].中国生化药物杂志,2017,37(6):364-365. 被引量:10
-
9杨湛南,方文,黄茜.幽门螺杆菌感染对冠心病患者抗血小板治疗后上消化道出血的影响[J].贵州医科大学学报,2017,42(9):1050-1054. 被引量:19
-
10张倩倩,郑松柏.老年“双抗”患者的胃黏膜损害及其保护策略[J].胃肠病学,2018,23(1):3-7. 被引量:4
-
1王敬,焦君良,要丽英.血瘀与溃疡性结肠炎关系的研究进展[J].河北中医,2008,30(1):95-97. 被引量:9
-
2任美书,冯淑芝,肖广辉,钟述猷.血小板活化功能检测对不稳定心绞痛的诊断意义[J].天津医药,1999,27(12):748-749.
-
3李梦梦,李全,陈方.双联抗血小板治疗期间高血小板活性及功能检测的意义[J].中国循环杂志,2016,31(12):1235-1237.
-
4金兰,张抒扬,严晓伟,许澎淮,朱广瑾,方圻.急性心肌梗塞患者溶栓治疗期间纤溶活性和血小板功能的变化及其临床意义[J].中华心血管病杂志,1995,23(4):261-263. 被引量:16
-
5原芳,王丽霞.白大衣高血压患者的血小板功能[J].临床心血管病杂志,2009,25(10):733-735.
-
6韦炜,楼正团.慢性乙型肝炎患者血小板参数变化的临床观察[J].临床荟萃,2005,20(4):220-221. 被引量:4
-
7王燕慧,张灏,金永新.抗血小板治疗中血小板聚集功能检测的现状[J].国际检验医学杂志,2011,32(17):1976-1978. 被引量:12
-
8马学斌,马聪,王倩,赵强元,杨明,刘敏.2型糖尿病患者血管病变相关指标的检测及其临床意义[J].解放军医学杂志,2013,38(10):851-854. 被引量:20
-
9苗青,吴伟利,张志联,薛玲,李亮,郝国贞.氯吡格雷低反应的AMI患者围术期加量应用氯吡格雷的疗效及安全性[J].中国老年学杂志,2010,30(4):530-531. 被引量:3
-
10于茜,王凡,刘宏斌,肖湖南.老年查体人群抗血小板药物应用的现况分析[J].中华老年多器官疾病杂志,2016,15(12):902-906. 被引量:3